Sarilumab vs tocilizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: IL-6 receptor · full Rheumatoid Arthritis pipeline
Sarilumab
Marketed by Sanofi and partners
NCT01061736 · Phase 2/3 · completed
This was a large, randomized, triple-blind, placebo-controlled trial with adequate sample size and hard clinical/functional/radiographic primary endpoints (ACR20 response, HAQ-DI, and van der Heijde-modified Total Sharp Score). In the confirmatory Part B, both sarilumab 150 mg and 200 mg every 2 weeks met all three primary endpoints with highly significant differences from placebo (p<0.0001), and Part A also showed significant ACR20 responses for several sarilumab doses. The positive, well-designed confirmatory results support strong evidence for sarilumab.
Next expected readout: March 2028 · NCT03414502 (registry estimate)
Reported efficacy
DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 (Baseline, Week 24): DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 (Baseline, Week 24): Sarilumab 200 mg/Sarilumab 200 mg -3.28 units on a scale (Standard Error 0.105) vs Adalimumab 40 mg/Sarilumab 200 mg -2.2 units on a scale (Standard Error 0.106) (met)
Result source: NCT02332590
tocilizumab · Actemra / RoActemra
Marketed by Roche and partners
NCT03155347 · Phase 3 · completed
This randomized, double-blind, active-comparator trial of 340 participants met its primary endpoint: about half of tocilizumab-treated patients achieved an ACR20 response at 24 weeks, compared with a quarter on methotrexate alone, a highly statistically significant difference for both the combination and monotherapy arms.
Next expected readout: August 2028 · NCT05869955 (registry estimate)
Reported efficacy
Percentage of Participants With an American College of Rheumatology (ACR) 20 (ACR20) Response at Week 24: ACR20 response at Week 24: tocilizumab+methotrexate 52.9% (72/136) vs methotrexate alone 25.0% (17/68), difference 27.9pp (95% CI 14.7-41.2), P<.001; tocilizumab monotherapy 50.0% (68/136) vs methotrexate alone 25.0%, difference 25.0pp (95% CI 11.7-38.3), P<.001 (met)
Result source: NCT03155347
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Sarilumab | tocilizumab |
|---|---|---|
| ACR20 | 66.4% vs 33.4%+33 vs placeboNCT0106173611 other results
| 60.9% vs 31.5%+29.4 vs placeboNCT012325698 other results
|
| ACR50 | 40.8% vs 18.2%+22.6 vs placeboNCT017095782 other results
| 32.2% vs 9.7%+22.5 vs placeboNCT001065355 other results
|
| ACR70 | 16.3% vs 7.2%+9.1 vs placeboNCT017095782 other results
| 12.6% vs 2%+10.6 vs placeboNCT001065355 other results
|
| DAS28-CRP remission | 28.8% vs 7.2%+21.6 vs placeboNCT017095784 other results
| —Not posted · NCT00106548 |
| HAQ-DI, change | -0.5 vs -0.3−0.2 vs placeboNCT017095784 other results
| -0.5 vs -0.3−0.2 vs placeboNCT012325696 other results
|
| Modified Sharp score, change | —Trial running · NCT03414502 | 0.4 vs 2.0−1.6 vs placeboNCT001065358 other results
|
ACR20
- Sarilumab
- 66.4% vs 33.4%+33 vs placeboNCT01061736
11 other results
- 60.9% vs 33.7% NCT01709578
- 58% vs 33.4% NCT01061736
- 57.5% vs 14.8% NCT02293902
- 55.8% vs 33.7% NCT01709578
- 65.4% vs 46.2% NCT01061736
- 67.9% vs 14.8% NCT02293902
- 72% vs 46.2% NCT01061736
- 66.7% vs 46.2% NCT01061736
- 62% vs 46.2% NCT01061736
- 49% vs 46.2% NCT01061736
- 71.7% vs 58.4% NCT02332590
- tocilizumab
- 60.9% vs 31.5%+29.4 vs placeboNCT01232569
8 other results
- 56.3% vs 27% NCT00106535
- 50.6% vs 27% NCT00106535
- 55.8% vs 24.7% NCT00106535
- 54.5% vs 29.3% NCT00106535
- 47.9% vs 24.7% NCT00106535
- 49.1% vs 29.3% NCT00106535
- 52.9% vs 25% NCT03155347
- 50% vs 25% NCT03155347
ACR50
- Sarilumab
- 40.8% vs 18.2%+22.6 vs placeboNCT01709578
2 other results
- 37% vs 18.2% NCT01709578
- 45.7% vs 29.7% NCT02332590
- tocilizumab
- 32.2% vs 9.7%+22.5 vs placeboNCT00106535
5 other results
- 36.4% vs 10.2% NCT00106535
- 38.9% vs 19.8% NCT00106535
- 25.1% vs 9.7% NCT00106535
- 30.3% vs 10.2% NCT00106535
- 37.6% vs 19.8% NCT00106535
ACR70
- Sarilumab
- 16.3% vs 7.2%+9.1 vs placeboNCT01709578
2 other results
- 19.9% vs 7.2% NCT01709578
- 23.4% vs 11.9% NCT02332590
- tocilizumab
- 12.6% vs 2%+10.6 vs placeboNCT00106535
5 other results
- 20.1% vs 3.8% NCT00106535
- 22.4% vs 12.2% NCT00106535
- 11% vs 2% NCT00106535
- 16.5% vs 3.8% NCT00106535
- 24.3% vs 12.2% NCT00106535
DAS28-CRP remission
- Sarilumab
- 28.8% vs 7.2%+21.6 vs placeboNCT01709578
4 other results
- 17.9% vs 3.9% NCT01709578
- 24.9% vs 7.2% NCT01709578
- 17.1% vs 3.9% NCT01709578
- 34.2% vs 13.5% NCT02332590
- tocilizumab
- —Not posted · NCT00106548
HAQ-DI, change
- Sarilumab
- -0.5 vs -0.3−0.2 vs placeboNCT01709578
4 other results
- -0.5 vs -0.3 NCT01709578
- -0.6 vs -0.3 NCT01709578
- -0.5 vs -0.3 NCT01709578
- -0.6 vs -0.4 NCT02332590
- tocilizumab
- -0.5 vs -0.3−0.2 vs placeboNCT01232569
6 other results
- -0.5 vs -0.3 NCT00106535
- -0.6 vs -0.4 NCT00106535
- -0.6 vs -0.5 NCT00106535
- -0.5 vs -0.3 NCT00106535
- -0.5 vs -0.4 NCT00106535
- -0.6 vs -0.5 NCT00106535
Modified Sharp score, change
- Sarilumab
- —Trial running · NCT03414502
- tocilizumab
- 0.4 vs 2.0−1.6 vs placeboNCT00106535
8 other results
- 0.3 vs 1.1 NCT00106535
- 0.6 vs 2.0 NCT00106535
- 0.3 vs 1.1 NCT00106535
- 0.6 vs 1.2 NCT01232569
- 0.3 vs 1.6 NCT00106535
- 0.2 vs 0.5 NCT00106535
- 0.5 vs 1.6 NCT00106535
- 0.2 vs 0.5 NCT00106535
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
20 other shared endpoints and safety
Coverage. Sarilumab: 24 of 24 rows · tocilizumab: 24 of 24 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Sarilumab Rows use multiple source trials | tocilizumab Rows use multiple source trials |
|---|---|---|
| ACR20 responder rate · % of participants No placebo or comparator arm | 82.9% (n=1898) @ 48wka,b NCT01146652 · Phase 3 · combination show 1 more dose85% (n=111) @ 48wk NCT01146652 · Phase 3 · monotherapy | 13.5% (n=96) @ 48wk*b NCT01941095 · Phase 3 · other · converted to % from 13 participants as posted 2 other source trials62.1% (n=140) @ 48wk* NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 87 participants as posted 57.1% (n=21) @ 48wk* NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 12 participants as posted |
| ACR20 responder rate · % of participants No placebo or comparator arm ACR20 | 40% (n=15) @ 52wk200 mg q2wa,b,c,d NCT02373202 · Phase 3 · registry result, not featured evidence · combination show 1 more dose73.3% (n=15) @ 52wk150 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · combination | 2 other source trials |
| ACR50 responder rate · % of participants No placebo or comparator arm | 62.4% (n=1897) @ 48wka,b NCT01146652 · Phase 3 · combination show 1 more dose69.2% (n=111) @ 48wk NCT01146652 · Phase 3 · monotherapy | 52.1% (n=140) @ 48wk*a,b NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 73 participants as posted show 1 more dose52.4% (n=21) @ 48wk* NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 11 participants as posted |
| ACR50 responder rate · % of participants No placebo or comparator arm ACR50 | 33.3% (n=15) @ 52wk200 mg q2wa,b,c,d NCT02373202 · Phase 3 · registry result, not featured evidence · combination show 1 more dose60% (n=15) @ 52wk150 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · combination | 2 other source trials |
| ACR70 responder rate · % of participants No placebo or comparator arm | 40.6% (n=1901) @ 48wka,b NCT01146652 · Phase 3 · combination show 1 more dose43.8% (n=111) @ 48wk NCT01146652 · Phase 3 · monotherapy | 40% (n=140) @ 48wk*a,b NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 56 participants as posted show 1 more dose38.1% (n=21) @ 48wk* NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 8 participants as posted |
| ACR70 responder rate · % of participants No placebo or comparator arm ACR70 | 26.7% (n=15) @ 52wk200 mg q2wa,b,c,d NCT02373202 · Phase 3 · registry result, not featured evidence · combination show 1 more dose53.3% (n=15) @ 52wk150 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · combination | 2 other source trials |
| CDAI absolute change · score No placebo or comparator arm | -14.6 score @ 24wkb,c NCT03449758 · Phase 4 · registry result, not featured evidence | 0.321 score @ 24wka,b,c NCT02573012 · Phase 4 · registry result, not featured evidence · combination show 1 more dose2.663 score @ 24wk NCT02573012 · Phase 4 · registry result, not featured evidence · combination |
| DAS28 Remission responder rate · % of participants No placebo or comparator arm | 57% (n=1873) @ 96wka,e,b NCT01146652 · Phase 3 · combination show 1 more dose71.7% (n=110) @ 96wk NCT01146652 · Phase 3 · monotherapy | 45.8% (n=115) @ 96wke,b NCT01149057 · Phase 4 · registry result, not featured evidence 1 other source trial41.2% (n=68) NCT01219933 · Phase 4 · registry result, not featured evidence |
| DAS28-ESR absolute change · score | -3.28 vs -2.2 Adalimumab score @ 24wk200 mgb,f NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 | -3.28 vs -1.49 placebo score @ 24wk8 mg/kga,b,f NCT00106535 · Phase 3 · combination show 1 more dose-2.45 vs -1.49 placebo score @ 24wk4 mg/kg NCT00106535 · Phase 3 · combination |
| DAS28-ESR absolute change · score No placebo or comparator arm | -2.7 score @ 24wkg,b,c NCT03449758 · Phase 4 · registry result, not featured evidence | -3.14 score @ 24wkg,b,c NCT01941095 · Phase 3 · other 15 other source trials-3.24 score @ 24wk NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 -3.21 score @ 24wk NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 -0.075 score @ 24wk NCT02573012 · Phase 4 · registry result, not featured evidence · combination 0.538 score @ 24wk NCT02573012 · Phase 4 · registry result, not featured evidence · combination -3.3 score @ 24wk NCT02046616 · Phase 3 · registry result, not featured evidence · combination -3.33 score @ 24wk NCT02046603 · Phase 3 · registry result, not featured evidence · combination -1.63 score NCT02046603 · Phase 3 · registry result, not featured evidence · combination -3.28 score @ 24wk NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy -2.88 score NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy -3.2 score @ 24wk NCT01941940 · Phase 3 · registry result, not featured evidence 3.232 score @ 24wk NCT01987479 · Phase 3 · registry result, not featured evidence · combination -3.3 score @ 24wk NCT02001987 · Phase 3 · registry result, not featured evidence -3.07 score @ 24wk NCT02001987 · Phase 3 · registry result, not featured evidence -3.01 score @ 24wk NCT02001987 · Phase 3 · registry result, not featured evidence -2.47 score @ 24wk NCT01988012 · Phase 3 · registry result, not featured evidence |
| FACIT-Fatigue absolute change · score | 10.18 vs 8.41 Adalimumab score @ 24wk200 mgb,f NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 2 other source trials9.86 vs 6.82 placebo score @ 24wk150 mg q2w NCT01709578 · Phase 3 10.06 vs 6.82 placebo score @ 24wk200 mg q2w NCT01709578 · Phase 3 | 6.91 vs 5.32 placebo score @ 24wk8 mg/kga,b,f NCT00106535 · Phase 3 · combination show 1 more dose7.14 vs 5.32 placebo score @ 24wk4 mg/kg NCT00106535 · Phase 3 · combination |
| FACIT-Fatigue absolute change · score No placebo or comparator arm | 11.09 score @ 96wke,b,c NCT01146652 · Phase 3 · combination | 7.3 score @ 96wka,e,b,c NCT01149057 · Phase 4 · registry result, not featured evidence show 1 more dose7.3 score @ 96wk NCT01149057 · Phase 4 · registry result, not featured evidence |
| HAQ-DI absolute change · score No placebo or comparator arm | -0.72 score @ 96wka,e,b NCT01146652 · Phase 3 · combination show 1 more dose-0.69 score @ 96wk NCT01146652 · Phase 3 · monotherapy | -0.5 score @ 96wke,b NCT01149057 · Phase 4 · registry result, not featured evidence |
| HAQ-DI absolute value · score No placebo or comparator arm | 0.8 score @ 24wkb,c NCT03449758 · Phase 4 · registry result, not featured evidence | 0.551 score @ 24wk8 mg/kgb,c NCT01089023 · Phase 4 · registry result, not featured evidence 5 other source trials0.84 score @ 24wk NCT00996203 · Phase 4 · registry result, not featured evidence 1.16 score @ 24wk8 mg/kg NCT01010503 · Phase 4 · registry result, not featured evidence 1.261 score @ 24wk NCT02046603 · Phase 3 · registry result, not featured evidence · combination 1.33 score @ 24wk NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy 0.6681 score @ 24wk NCT01987479 · Phase 3 · registry result, not featured evidence · combination |
| Modified Sharp absolute change · score No placebo or comparator arm | 2.83 score @ 192wkb,c,h NCT01146652 · Phase 3 · combination | 0 score @ 24wkb,c,h NCT01951170 · Phase 3 · registry result, not featured evidence |
| Pain VAS absolute change · mm No placebo or comparator arm | -38.46 mm @ 60wka,b NCT01146652 · Phase 3 · combination show 1 more dose-40.79 mm @ 60wk NCT01146652 · Phase 3 · monotherapy | -42 mm @ 60wkb NCT02001987 · Phase 3 · registry result, not featured evidence |
| Patient Global VAS absolute change · mm No placebo or comparator arm | -36.91 mm @ 24wka,b NCT01146652 · Phase 3 · combination show 1 more dose-36.12 mm @ 24wk NCT01146652 · Phase 3 · monotherapy | -34.3 mm @ 24wkb NCT02046616 · Phase 3 · registry result, not featured evidence · combination 3 other source trials-28.4 mm @ 24wk NCT01941940 · Phase 3 · registry result, not featured evidence 19 mm @ 24wk NCT01995201 · Phase 3 · registry result, not featured evidence · combination 16.63 mm @ 24wk NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy |
| Patient Global VAS absolute value · mm No placebo or comparator arm | 34.6 mm @ 24wkg,b NCT03449758 · Phase 4 · registry result, not featured evidence | 26.6 mm @ 24wka,g,b NCT02046603 · Phase 3 · registry result, not featured evidence · combination show 1 more dose23.8 mm @ 24wk NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy |
| Physician Global VAS absolute change · mm No placebo or comparator arm | -48.39 mm @ 24wka,b NCT01146652 · Phase 3 · combination show 1 more dose-50.82 mm @ 24wk NCT01146652 · Phase 3 · monotherapy | -38 mm @ 24wkb NCT01941940 · Phase 3 · registry result, not featured evidence |
| RAID absolute change · score No placebo or comparator arm | -2.4 score @ 24wkb,c NCT03449758 · Phase 4 · registry result, not featured evidence | -0.22 score @ 24wka,b,c NCT02573012 · Phase 4 · registry result, not featured evidence · combination show 1 more dose0.469 score @ 24wk NCT02573012 · Phase 4 · registry result, not featured evidence · combination |
| Dropout rate | 13.5%200 mg q2wi NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 show 35 more results—200 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 5.9%150 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 8%150 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 —150 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 —150 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 11.8%100 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 26%100 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 —100 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 —100 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 49.7%Sarilumab + Disease Modifying Anti NCT01146652 · Phase 3 · combination 40.5%Sarilumab Monotherapy NCT01146652 · Phase 3 · monotherapy —200 mg NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —200 mg NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 10.3%200 mg NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 27.7%200 mg q2w NCT01709578 · Phase 3 30.9%150 mg q2w NCT01709578 · Phase 3 22.6% NCT03449758 · Phase 4 · registry result, not featured evidence —200 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy —150 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy 40%200 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · combination 13.3%150 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · combination 12.5%200 mg NCT02293902 · Phase 3 · registry result, not featured evidence 8.6%150 mg NCT02293902 · Phase 3 · registry result, not featured evidence —Sarilumab Rescue NCT02293902 · Phase 3 · registry result, not featured evidence 13.5%200 mg NCT02057250 · Phase 3 · registry result, not featured evidence 3.6%200 mg NCT02057250 · Phase 3 · registry result, not featured evidence 7.1%150 mg NCT02057250 · Phase 3 · registry result, not featured evidence 5.7%150 mg NCT02057250 · Phase 3 · registry result, not featured evidence —150 mg NCT02057250 · Phase 3 · registry result, not featured evidence 13.4%200 mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence —200mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence 10.8%150 mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence —150mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence 23.5%200 mg q2w NCT01768572 · Phase 3 · registry result, not featured evidence 18.4%150 mg q2w NCT01768572 · Phase 3 · registry result, not featured evidence | 57.7%Tocilizumabj NCT01941095 · Phase 3 · other show 49 more results—Tocilizumab + Methotrexate or Othe NCT01941095 · Phase 3 · combination —Tocilizumab Monotherapy NCT01941095 · Phase 3 · monotherapy 19.3% NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —8 mg/kg NCT00106535 · Phase 3 · combination 22.7%8 mg/kg NCT00106535 · Phase 3 · combination —4 mg/kg NCT00106535 · Phase 3 · combination 22.9%4 mg/kg NCT00106535 · Phase 3 · combination 10.6%Tocilizumab IV NCT01194414 · Phase 3 —Tocilizumab IV Then Tocilizumab SC NCT01194414 · Phase 3 9.4%Tocilizumab SC NCT01194414 · Phase 3 —Tocilizumab SC Then Tocilizumab IV NCT01194414 · Phase 3 —Tocilizumab Pre-filled Syringe NCT01232569 · Phase 3 —Tocilizumab Pre-filled Syringe to NCT01232569 · Phase 3 3.6% NCT01331837 · Phase 4 11.7%Tocilizumab+Prednisone (Constant D NCT02573012 · Phase 4 · registry result, not featured evidence · combination 11.5%Tocilizumab+Prednisone (Tapering D NCT02573012 · Phase 4 · registry result, not featured evidence · combination 18.5% NCT01717859 · Phase 4 · registry result, not featured evidence 3.8% NCT01715831 · Phase 4 · registry result, not featured evidence 39.3% NCT01149057 · Phase 4 · registry result, not featured evidence —TCZ + MTX (Not Randomized) NCT01399697 · Phase 4 · registry result, not featured evidence · combination —TCZ + MTX (Post-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence · combination —TCZ + MTX (Pre-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence · combination 3.6%TCZ + MTX (Randomized) NCT01399697 · Phase 4 · registry result, not featured evidence · combination —TCZ + Placebo (Post-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence —TCZ + Placebo (Pre-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence 4.9%TCZ + Placebo (Randomized) NCT01399697 · Phase 4 · registry result, not featured evidence 55.9% NCT01219933 · Phase 4 · registry result, not featured evidence 18.3% NCT01163747 · Phase 4 · registry result, not featured evidence · combination —8 mg/kg NCT01195272 · Phase 4 · registry result, not featured evidence 14.7%8 mg/kg NCT01119859 · Phase 4 · registry result, not featured evidence — NCT01089023 · Phase 4 · registry result, not featured evidence —8 mg/kg NCT01034397 · Phase 4 · registry result, not featured evidence 3.5% NCT00996203 · Phase 4 · registry result, not featured evidence — NCT02010216 · Phase 4 · registry result, not featured evidence —8 mg/kg NCT01010503 · Phase 4 · registry result, not featured evidence 14.3% NCT02046616 · Phase 3 · registry result, not featured evidence · combination 68.2%Tocilizumab Monotherapy NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy 53.6%Tocilizumab in Combination With Me NCT02046603 · Phase 3 · registry result, not featured evidence · combination 14.5% NCT01941940 · Phase 3 · registry result, not featured evidence 11.3% NCT01987479 · Phase 3 · registry result, not featured evidence · combination 17.4% NCT01668966 · Phase 3 · registry result, not featured evidence 14.1%Phase 1: Combination Therapy NCT01995201 · Phase 3 · registry result, not featured evidence · combination 13.5%Phase 1: Tocilizumab Monotherapy NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy 16.5%TCZ - All Participants NCT02001987 · Phase 3 · registry result, not featured evidence —TCZ MONO - All Participants NCT02001987 · Phase 3 · registry result, not featured evidence 18.2% NCT01734993 · Phase 3 · registry result, not featured evidence 1.9% NCT01951170 · Phase 3 · registry result, not featured evidence 20% NCT01655381 · Phase 3 · registry result, not featured evidence 15% NCT01988012 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 7.7%200 mg q2wi NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 show 35 more results—200 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 3.9%150 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 2%150 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 —150 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 —150 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 5.9%100 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 26%100 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 —100 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 —100 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 26.5%Sarilumab + Disease Modifying Anti NCT01146652 · Phase 3 · combination 13.5%Sarilumab Monotherapy NCT01146652 · Phase 3 · monotherapy —200 mg NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —200 mg NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 6%200 mg NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 9.2%200 mg q2w NCT01709578 · Phase 3 9.9%150 mg q2w NCT01709578 · Phase 3 10.7% NCT03449758 · Phase 4 · registry result, not featured evidence —200 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy —150 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy 33.3%200 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · combination 13.3%150 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · combination 10%200 mg NCT02293902 · Phase 3 · registry result, not featured evidence 7.4%150 mg NCT02293902 · Phase 3 · registry result, not featured evidence —Sarilumab Rescue NCT02293902 · Phase 3 · registry result, not featured evidence 11.5%200 mg NCT02057250 · Phase 3 · registry result, not featured evidence 1.8%200 mg NCT02057250 · Phase 3 · registry result, not featured evidence 5.4%150 mg NCT02057250 · Phase 3 · registry result, not featured evidence 3.8%150 mg NCT02057250 · Phase 3 · registry result, not featured evidence —150 mg NCT02057250 · Phase 3 · registry result, not featured evidence 10.4%200 mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence —200mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence 7.7%150 mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence —150mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence 17.6%200 mg q2w NCT01768572 · Phase 3 · registry result, not featured evidence 16.3%150 mg q2w NCT01768572 · Phase 3 · registry result, not featured evidence | 11.3%Tocilizumabj NCT01941095 · Phase 3 · other show 49 more results—Tocilizumab + Methotrexate or Othe NCT01941095 · Phase 3 · combination —Tocilizumab Monotherapy NCT01941095 · Phase 3 · monotherapy 10.5% NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —8 mg/kg NCT00106535 · Phase 3 · combination —8 mg/kg NCT00106535 · Phase 3 · combination —4 mg/kg NCT00106535 · Phase 3 · combination —4 mg/kg NCT00106535 · Phase 3 · combination 6.3%Tocilizumab IV NCT01194414 · Phase 3 —Tocilizumab IV Then Tocilizumab SC NCT01194414 · Phase 3 4.4%Tocilizumab SC NCT01194414 · Phase 3 —Tocilizumab SC Then Tocilizumab IV NCT01194414 · Phase 3 —Tocilizumab Pre-filled Syringe NCT01232569 · Phase 3 —Tocilizumab Pre-filled Syringe to NCT01232569 · Phase 3 — NCT01331837 · Phase 4 3.9%Tocilizumab+Prednisone (Constant D NCT02573012 · Phase 4 · registry result, not featured evidence · combination 3.8%Tocilizumab+Prednisone (Tapering D NCT02573012 · Phase 4 · registry result, not featured evidence · combination 9.3% NCT01717859 · Phase 4 · registry result, not featured evidence 3.8% NCT01715831 · Phase 4 · registry result, not featured evidence 9% NCT01149057 · Phase 4 · registry result, not featured evidence —TCZ + MTX (Not Randomized) NCT01399697 · Phase 4 · registry result, not featured evidence · combination —TCZ + MTX (Post-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence · combination —TCZ + MTX (Pre-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence · combination 3.6%TCZ + MTX (Randomized) NCT01399697 · Phase 4 · registry result, not featured evidence · combination —TCZ + Placebo (Post-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence —TCZ + Placebo (Pre-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence 1.2%TCZ + Placebo (Randomized) NCT01399697 · Phase 4 · registry result, not featured evidence 11.8% NCT01219933 · Phase 4 · registry result, not featured evidence 8.3% NCT01163747 · Phase 4 · registry result, not featured evidence · combination —8 mg/kg NCT01195272 · Phase 4 · registry result, not featured evidence 5.5%8 mg/kg NCT01119859 · Phase 4 · registry result, not featured evidence — NCT01089023 · Phase 4 · registry result, not featured evidence —8 mg/kg NCT01034397 · Phase 4 · registry result, not featured evidence 1.5% NCT00996203 · Phase 4 · registry result, not featured evidence — NCT02010216 · Phase 4 · registry result, not featured evidence —8 mg/kg NCT01010503 · Phase 4 · registry result, not featured evidence 9.8% NCT02046616 · Phase 3 · registry result, not featured evidence · combination 0%Tocilizumab Monotherapy NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy 0.7%Tocilizumab in Combination With Me NCT02046603 · Phase 3 · registry result, not featured evidence · combination 4.8% NCT01941940 · Phase 3 · registry result, not featured evidence 4.7% NCT01987479 · Phase 3 · registry result, not featured evidence · combination — NCT01668966 · Phase 3 · registry result, not featured evidence 4.6%Phase 1: Combination Therapy NCT01995201 · Phase 3 · registry result, not featured evidence · combination 5.4%Phase 1: Tocilizumab Monotherapy NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy 6.5%TCZ - All Participants NCT02001987 · Phase 3 · registry result, not featured evidence —TCZ MONO - All Participants NCT02001987 · Phase 3 · registry result, not featured evidence 9.1% NCT01734993 · Phase 3 · registry result, not featured evidence — NCT01951170 · Phase 3 · registry result, not featured evidence — NCT01655381 · Phase 3 · registry result, not featured evidence 5% NCT01988012 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 0%200 mg q2wi NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 show 35 more results12.5%200 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 0%150 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 0%150 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 9.5%150 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 7.7%150 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 5.9%100 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 6%100 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 0%100 mg q2w NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 6.9%100 mg qw NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 32.3%Sarilumab + Disease Modifying Anti NCT01146652 · Phase 3 · combination 24.3%Sarilumab Monotherapy NCT01146652 · Phase 3 · monotherapy 4.9%200 mg NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 17.5%200 mg NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —200 mg NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 5.4%200 mg q2w NCT01709578 · Phase 3 3.3%150 mg q2w NCT01709578 · Phase 3 11.9% NCT03449758 · Phase 4 · registry result, not featured evidence 6.5%200 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy 3.3%150 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy 20%200 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · combination 0%150 mg q2w NCT02373202 · Phase 3 · registry result, not featured evidence · combination 6.3%200 mg NCT02293902 · Phase 3 · registry result, not featured evidence 9.9%150 mg NCT02293902 · Phase 3 · registry result, not featured evidence 6.9%Sarilumab Rescue NCT02293902 · Phase 3 · registry result, not featured evidence 5.8%200 mg NCT02057250 · Phase 3 · registry result, not featured evidence 7.1%200 mg NCT02057250 · Phase 3 · registry result, not featured evidence 1.8%150 mg NCT02057250 · Phase 3 · registry result, not featured evidence 0%150 mg NCT02057250 · Phase 3 · registry result, not featured evidence 10.1%150 mg NCT02057250 · Phase 3 · registry result, not featured evidence —200 mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence 3%200mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence —150 mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence 1.5%150mg q2w NCT02121210 · Phase 3 · registry result, not featured evidence 5.9%200 mg q2w NCT01768572 · Phase 3 · registry result, not featured evidence 2%150 mg q2w NCT01768572 · Phase 3 · registry result, not featured evidence | —Tocilizumabj NCT01941095 · Phase 3 · other show 49 more results7.6%Tocilizumab + Methotrexate or Othe NCT01941095 · Phase 3 · combination 6.5%Tocilizumab Monotherapy NCT01941095 · Phase 3 · monotherapy 8.8% NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 25.3%8 mg/kg NCT00106535 · Phase 3 · combination —8 mg/kg NCT00106535 · Phase 3 · combination 9.7%4 mg/kg NCT00106535 · Phase 3 · combination —4 mg/kg NCT00106535 · Phase 3 · combination 12.7%Tocilizumab IV NCT01194414 · Phase 3 11.3%Tocilizumab IV Then Tocilizumab SC NCT01194414 · Phase 3 13.9%Tocilizumab SC NCT01194414 · Phase 3 12.5%Tocilizumab SC Then Tocilizumab IV NCT01194414 · Phase 3 8.2%Tocilizumab Pre-filled Syringe NCT01232569 · Phase 3 10.1%Tocilizumab Pre-filled Syringe to NCT01232569 · Phase 3 31.1% NCT01331837 · Phase 4 3.1%Tocilizumab+Prednisone (Constant D NCT02573012 · Phase 4 · registry result, not featured evidence · combination 5.3%Tocilizumab+Prednisone (Tapering D NCT02573012 · Phase 4 · registry result, not featured evidence · combination 1.9% NCT01717859 · Phase 4 · registry result, not featured evidence 15.4% NCT01715831 · Phase 4 · registry result, not featured evidence 24.8% NCT01149057 · Phase 4 · registry result, not featured evidence 11.5%TCZ + MTX (Not Randomized) NCT01399697 · Phase 4 · registry result, not featured evidence · combination 1.2%TCZ + MTX (Post-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence · combination 0%TCZ + MTX (Pre-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence · combination —TCZ + MTX (Randomized) NCT01399697 · Phase 4 · registry result, not featured evidence · combination 4.9%TCZ + Placebo (Post-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence 1.2%TCZ + Placebo (Pre-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence —TCZ + Placebo (Randomized) NCT01399697 · Phase 4 · registry result, not featured evidence — NCT01219933 · Phase 4 · registry result, not featured evidence 5% NCT01163747 · Phase 4 · registry result, not featured evidence · combination 19%8 mg/kg NCT01195272 · Phase 4 · registry result, not featured evidence 11.7%8 mg/kg NCT01119859 · Phase 4 · registry result, not featured evidence 8.4% NCT01089023 · Phase 4 · registry result, not featured evidence 5.7%8 mg/kg NCT01034397 · Phase 4 · registry result, not featured evidence 6% NCT00996203 · Phase 4 · registry result, not featured evidence 0% NCT02010216 · Phase 4 · registry result, not featured evidence 9.4%8 mg/kg NCT01010503 · Phase 4 · registry result, not featured evidence 9% NCT02046616 · Phase 3 · registry result, not featured evidence · combination 14.3%Tocilizumab Monotherapy NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy 5%Tocilizumab in Combination With Me NCT02046603 · Phase 3 · registry result, not featured evidence · combination 7.5% NCT01941940 · Phase 3 · registry result, not featured evidence 9.3% NCT01987479 · Phase 3 · registry result, not featured evidence · combination 9.5% NCT01668966 · Phase 3 · registry result, not featured evidence 3.1%Phase 1: Combination Therapy NCT01995201 · Phase 3 · registry result, not featured evidence · combination 4.1%Phase 1: Tocilizumab Monotherapy NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy 11.5%TCZ - All Participants NCT02001987 · Phase 3 · registry result, not featured evidence 11.6%TCZ MONO - All Participants NCT02001987 · Phase 3 · registry result, not featured evidence 18.2% NCT01734993 · Phase 3 · registry result, not featured evidence 5.8% NCT01951170 · Phase 3 · registry result, not featured evidence 6.7% NCT01655381 · Phase 3 · registry result, not featured evidence 6% NCT01988012 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 200 mg q2wi neutropenia 19.6% (placebo 0%) upper respiratory tract infection 5.9% (placebo 3.9%) accidental overdose 3.9% (placebo 9.8%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 show 32 more results200 mg q2w neutropenia 14.9% (placebo 0%) upper respiratory tract infection 9.5% (placebo 3.9%) alanine aminotransferase increased 8.1% (placebo 0%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 150 mg q2w accidental overdose 5.8% (placebo 9.8%) alanine aminotransferase increased 5.8% (placebo 0%) nasopharyngitis 3.8% (placebo 5.9%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 150 mg qw neutropenia 10% (placebo 0%) accidental overdose 6% (placebo 9.8%) rheumatoid arthritis 6% (placebo 2%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 150 mg q2w neutropenia 9.7% (placebo 0%) alanine aminotransferase increased 8.4% (placebo 0%) upper respiratory tract infection 8.4% (placebo 3.9%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 150 mg qw injection site erythema 11.5% (placebo 0%) hypertension 7.7% (placebo 2%) neutropenia 7.7% (placebo 0%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 100 mg q2w hypertension 3.9% (placebo 2%) nasopharyngitis 3.9% (placebo 5.9%) accidental overdose 2% (placebo 9.8%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 100 mg qw neutropenia 12% (placebo 0%) urinary tract infection 6% (placebo 2%) accidental overdose 4% (placebo 9.8%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 100 mg q2w accidental overdose 10.3% (placebo 9.8%) hypertension 6.9% (placebo 2%) neutropenia 3.4% (placebo 0%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 100 mg qw accidental overdose 6.9% (placebo 9.8%) rheumatoid arthritis 6.9% (placebo 2%) hypertension 3.4% (placebo 2%) NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3 neutropenia 18.2% accidental overdose 17.3% upper respiratory tract infection 15.9% NCT01146652 · Phase 3 · combination accidental overdose 18% neutropenia 16.2% rheumatoid arthritis 14.4% NCT01146652 · Phase 3 · monotherapy 200 mg neutropenia 13.6% injection site erythema 7.6% bronchitis 6.5% NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 200 mg nasopharyngitis 18.8% neutropenia 18.4% bronchitis 12.8% NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 200 mg q2w neutropenia 12% (placebo 1.1%) urinary tract infection 7.1% (placebo 6.6%) alanine aminotransferase increased 5.4% (placebo 1.1%) NCT01709578 · Phase 3 150 mg q2w neutropenia 12.7% (placebo 1.1%) hypertriglyceridaemia 6.1% (placebo 1.7%) injection site erythema 6.1% (placebo 0%) NCT01709578 · Phase 3 neutropenia 19% bronchitis 11.9% nausea 11.9% NCT03449758 · Phase 4 · registry result, not featured evidence 200 mg q2w nasopharyngitis 45.2% injection site erythema 19.4% hepatic function abnormal 12.9% NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy 150 mg q2w nasopharyngitis 43.3% rheumatoid arthritis 13.3% oropharyngeal pain 10% NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy 200 mg q2w nasopharyngitis 33.3% stomatitis 26.7% neutropenia 20% NCT02373202 · Phase 3 · registry result, not featured evidence · combination 150 mg q2w neutropenia 33.3% nasopharyngitis 26.7% contusion 20% NCT02373202 · Phase 3 · registry result, not featured evidence · combination 200 mg nasopharyngitis 28.8% (placebo 14.8%) neutropenia 11.3% (placebo 0%) stomatitis 10% (placebo 3.7%) NCT02293902 · Phase 3 · registry result, not featured evidence 150 mg nasopharyngitis 33.3% (placebo 14.8%) neutropenia 12.3% (placebo 0%) hepatic function abnormal 9.9% (placebo 4.9%) NCT02293902 · Phase 3 · registry result, not featured evidence nasopharyngitis 32.8% (placebo 14.8%) stomatitis 12.1% (placebo 3.7%) neutropenia 10.3% (placebo 0%) NCT02293902 · Phase 3 · registry result, not featured evidence 200 mg neutropenia 11.5% alanine aminotransferase increased 9.6% injection site erythema 7.7% NCT02057250 · Phase 3 · registry result, not featured evidence 200 mg injection site erythema 7.1% injection site pruritus 7.1% neutropenia 7.1% NCT02057250 · Phase 3 · registry result, not featured evidence 150 mg neutropenia 17.9% pharyngitis 8.9% bronchitis 7.1% NCT02057250 · Phase 3 · registry result, not featured evidence 150 mg neutropenia 17% sinusitis 5.7% injection site erythema 3.8% NCT02057250 · Phase 3 · registry result, not featured evidence 150 mg upper respiratory tract infection 13.3% neutropenia 6.4% sinusitis 6.4% NCT02057250 · Phase 3 · registry result, not featured evidence 200mg q2w neutropenia 16.4% hypertension 6% upper respiratory tract infection 6% NCT02121210 · Phase 3 · registry result, not featured evidence 150mg q2w neutropenia 12.3% injection site erythema 7.7% upper respiratory tract infection 4.6% NCT02121210 · Phase 3 · registry result, not featured evidence 200 mg q2w neutropenia 15.7% injection site erythema 7.8% accidental overdose 5.9% NCT01768572 · Phase 3 · registry result, not featured evidence 150 mg q2w nasopharyngitis 12.2% neutropenia 12.2% injection site erythema 8.2% NCT01768572 · Phase 3 · registry result, not featured evidence | j alanine aminotransferase increased 19.7% aspartate aminotransferase increased 13.6% leukopenia 12.1% NCT01941095 · Phase 3 · combination show 43 more resultsalanine aminotransferase increased 29% aspartate aminotransferase increased 25.8% neutropenia 19.4% NCT01941095 · Phase 3 · monotherapy bronchitis 15.8% cough 12.3% nasopharyngitis 12.3% NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 8 mg/kg upper respiratory tract infection 24.3% (placebo 7.4%) urinary tract infection 16.1% (placebo 5.1%) hypertension 13.4% (placebo 3.1%) NCT00106535 · Phase 3 · combination 4 mg/kg upper respiratory tract infection 9.2% (placebo 7.4%) hypertension 5.7% (placebo 3.1%) urinary tract infection 5.7% (placebo 5.1%) NCT00106535 · Phase 3 · combination alanine aminotransferase increased 22.2% upper respiratory tract infection 20.6% aspartate aminotransferase increased 15.2% NCT01194414 · Phase 3 upper respiratory tract infection 17.7% alanine aminotransferase increased 15.6% nasopharyngitis 14% NCT01194414 · Phase 3 alanine aminotransferase increased 29.8% aspartate aminotransferase increased 21.4% upper respiratory tract infection 19.3% NCT01194414 · Phase 3 upper respiratory tract infection 16.7% alanine aminotransferase increased 14.6% nasopharyngitis 14.6% NCT01194414 · Phase 3 alanine aminotransferase increased 15.3% (placebo 6%) upper respiratory tract infection 11.9% (placebo 6.4%) aspartate aminotransferase increased 9.2% (placebo 4.6%) NCT01232569 · Phase 3 alanine aminotransferase increased 14.3% (placebo 6%) upper respiratory tract infection 12.5% (placebo 6.4%) nasopharyngitis 9.5% (placebo 2.3%) NCT01232569 · Phase 3 nasopharyngitis 7% diarrhoea 3.9% alanine aminotransferase increased 2.3% NCT02573012 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 9.9% alanine aminotransferase increased 6.9% aspartate aminotransferase increased 6.9% NCT02573012 · Phase 4 · registry result, not featured evidence · combination rheumatoid arthritis flare 38.9% upper respiratory infection 38.9% hypercholesterolemia 31.5% NCT01717859 · Phase 4 · registry result, not featured evidence respiratory tract infection nos 46.2% musculoskeletal pain 30.8% urinary tract infection 26.9% NCT01715831 · Phase 4 · registry result, not featured evidence alanine aminotransferase/aspartate aminotransferase elevations 32.4% leukopenia 22.1% upper respiratory tract infection 17.2% NCT01149057 · Phase 4 · registry result, not featured evidence hypertransaminasaemia 15.6% hypercholesterolaemia 9.4% leukopenia 7.3% NCT01399697 · Phase 4 · registry result, not featured evidence · combination hypertransaminasaemia 9.6% aphthous stomatitis 0% hypercholesterolaemia 0% NCT01399697 · Phase 4 · registry result, not featured evidence · combination hypertransaminasaemia 14.5% aphthous stomatitis 3.6% urinary tract infection 3.6% NCT01399697 · Phase 4 · registry result, not featured evidence · combination hypertransaminasaemia 4.9% aphthous stomatitis 0% hypercholesterolaemia 0% NCT01399697 · Phase 4 · registry result, not featured evidence hypertransaminasaemia 12.2% aphthous stomatitis 7.3% hypercholesterolaemia 7.3% NCT01399697 · Phase 4 · registry result, not featured evidence sinusitis 8.3% headache 6.7% nausea 6.7% NCT01163747 · Phase 4 · registry result, not featured evidence · combination 8 mg/kg rheumatoid arthritis 47.6% lower respiratory tract infection 42.9% nasopharyngitis 38.1% NCT01195272 · Phase 4 · registry result, not featured evidence 8 mg/kg upper respiratory tract infection 11.1% nasopharyngitis 10.5% hypertension 8% NCT01119859 · Phase 4 · registry result, not featured evidence investigations 30.5% blood and lymphatic system disorders 7.4% infections and infestations 7.4% NCT01089023 · Phase 4 · registry result, not featured evidence 8 mg/kg urinary tract infection 11.4% (placebo 10%) hypercholesterolemia 8.6% (placebo 10%) elevated alt 5.7% (placebo 0%) NCT01034397 · Phase 4 · registry result, not featured evidence alanine aminotransferase increased 4.5% transaminases increased 4% respiratory tract infection 3% NCT00996203 · Phase 4 · registry result, not featured evidence drowsiness 8.7% NCT02010216 · Phase 4 · registry result, not featured evidence 8 mg/kg acute bronchitis 9.4% leucopenia+lymphopenia 9.4% hepatopathy 6.3% NCT01010503 · Phase 4 · registry result, not featured evidence nasopharyngitis 15% hypertension 12.8% nausea 8.3% NCT02046616 · Phase 3 · registry result, not featured evidence · combination lower respiratory tract infection 28.6% nasopharyngitis 23.8% urinary tract infection 23.8% NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy nasopharyngitis 23.6% diarrhoea 22.9% alanine aminotransferase increased 22.1% NCT02046603 · Phase 3 · registry result, not featured evidence · combination influenza 10.1% cough 7% bronchitis 6.6% NCT01941940 · Phase 3 · registry result, not featured evidence nasopharyngitis 23.3% fatigue 12% nausea 12% NCT01987479 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 42.9% dyslipidaemia 23.8% upper respiratory tract infection 19% NCT01668966 · Phase 3 · registry result, not featured evidence transaminases increased 11.3% upper respiratory tract infection 7% urinary tract infection 7% NCT01995201 · Phase 3 · registry result, not featured evidence · combination injection site erythema 8.1% urinary tract infection 8.1% back pain 5.4% NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy rheumatoid arthritis 13.7% bronchitis 11.5% rhinitis 9.4% NCT02001987 · Phase 3 · registry result, not featured evidence rheumatoid arthritis 18.6% bronchitis 16.3% ear infection 11.6% NCT02001987 · Phase 3 · registry result, not featured evidence bronchitis 45.5% arthralgia 36.4% urinary tract infection 27.3% NCT01734993 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 28.8% rheumatoid arthritis 21.2% neutropenia 11.5% NCT01951170 · Phase 3 · registry result, not featured evidence bronchitis 40% back pain 33.3% asthenia 26.7% NCT01655381 · Phase 3 · registry result, not featured evidence neutropenia 12% hepatic enzyme increased 11% leukopenia 11% NCT01988012 · Phase 3 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 52 weeks versus 24 weeks.
- eTrial phases differ: Phase 3 versus Phase 4.
- fTreatment context differs: monotherapy versus combination.
- gTrial phases differ: Phase 4 versus Phase 3.
- hAssessment timepoints differ: 192 weeks versus 24 weeks.
- iPopulation comparability has not been reviewed for 23 of these studies.
- jPopulation comparability has not been reviewed for 49 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Sarilumab
show 1 more result
show 50 more results
show 6 more results
show 48 more results
show 51 more results
show 15 more results
show 15 more results
show 2 more results
show 2 more results
show 4 more results
show 4 more results
+ 23 further endpoints in the CSV export.
tocilizumab
show 53 more results
show 84 more results
show 13 more results
show 13 more results
show 5 more results
show 5 more results
show 1 more result
show 1 more result
show 3 more results
show 1 more result
show 1 more result
+ 573 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Sarilumab's landscape · tocilizumab's landscape